2. UroToday Home
  3. Video Lectures

Localized Prostate Cancer Videos

Focal Therapy: Killing Cancer, Not the Prostate "Presentation" - Arvin George
November 19, 2024
Details
Challenges in Defining High-Risk Localized Prostate Cancer for Optimal Treatment "Presentation" - Martin Gleave
November 15, 2024
Details
What is the Role of DRE in the Modern Imaging Era? "Presentation" - Declan Murphy
November 15, 2024
Details
Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should be the Standard? “Presentation” - Jochen Walz
November 15, 2024
Details
Genomic Classifiers and Artificial Intelligence (AI) as Predictors for Treatment Benefit "Presentation" - Daniel Spratt
November 15, 2024
Details
Impact of Imaging and Biopsy Techniques on Treatment Decisions "Discussion"
November 15, 2024
Details
Radiation Therapy Schedules and Fields for Highrisk and Locally Advanced Prostate Cancer "Presentation" - Neha Vapiwala
November 15, 2024
Details
Surgery as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Alberto Briganti
November 15, 2024
Details
Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Piet Ost
November 15, 2024
Details
Surgery vs Radiation vs Multimodal Prostate Cancer Treatment "Discussion"
November 15, 2024
Details
How to Select Patients for Adjuvant Therapy After Radical Prostatectomy and How to Treat Them? "Presentation" - Jason Efstathiou
November 15, 2024
Details
How to Manage Patients with PSA Persistence Following Radical Prostatectomy? "Presentation" Derya Tilki
November 15, 2024
Details
How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can be Postponed? "Presentation" - Barbara Alicja Jereczek-Fossa
November 15, 2024
Details
Which Patients with High-Risk First BCR After Radical Prostatectomy are Candidates for Systemic Therapy Alone Without Local Salvage RT? "Presentation" - Bertrand Tombal
November 15, 2024
Details
In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt
November 15, 2024
Details
Timing of Salvage Radiotherapy in Recurrent Prostate Cancer Management "Discussion"
November 15, 2024
Details
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
November 5, 2024
Details
Exercise Benefits In Prostate Cancer Active Surveillance - Dong-Woo Kang
November 4, 2024
Details
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance - Andre Esteva
October 17, 2024
Details
Hypofractionated Radiotherapy Efficacy for Post-Prostatectomy Patients - Asunción Hervás
October 14, 2024
Details
Optimizing Post-Operative Care in Robotic Prostatectomy Same-Day Discharge - Brian Lane
October 14, 2024
Details
PACE-C Trial Results: SBRT vs Moderate Hypofractionation for High-Risk Prostate Cancer - Alison Tree
October 13, 2024
Details
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
October 1, 2024
Details
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
September 30, 2024
Details
Proton Therapy vs IMRT in Prostate Cancer PARTIQoL Trial - Jason Efstathiou
September 27, 2024
Details
PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer - Duncan Gilbert
September 26, 2024
Details
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
September 24, 2024
Details
Rising Out-of-Pocket Costs in Prostate Cancer Screening: A Growing Concern - Arnav Srivastava
August 30, 2024
Details
Transperineal vs Transrectal Prostate Biopsy: Trial Findings and Discussion - Badar Mian
August 22, 2024
Details
Transperineal vs Transrectal Prostate Biopsy: Clinical Trial Findings - Badar Mian
August 22, 2024
Details
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett
August 13, 2024
Details
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore
August 12, 2024
Details
Welcome and Background Cancer or Not Cancer "Presentation" - Scott Eggener
July 24, 2024
Details
Rationale for Nomenclature Change Gleason Grade 1 Cancer "Presentation" - Matthew Cooperberg
July 24, 2024
Details
Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel
July 24, 2024
Details
What is in a Name? Inadvertent Harm from the Designation and Label of 'Cancer' "Presentation" - Laura Esserman
July 24, 2024
Details
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Con' "Presentation" - Gladell Paner
July 24, 2024
Details
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Pro' "Presentation" - Theodorus van der Kwast
July 24, 2024
Details
Prostate Cancer Classification Dilemma: Lessons from Breast and Colorectal Tumors "Presentation" - Jeffry Simko
July 24, 2024
Details
Prostate Cancer Biopsy Sampling: Challenges in Grade Group 1 Classification "Discussion" - Lawrence True
July 24, 2024
Details
Rethinking Cancer Treatment: Lessons from Breast to Prostate Cancer "Presentation" - Alastair Lamb
July 24, 2024
Details
Where to Draw the Line? The Spatial Molecular Continuum from 'Normal' to GG1 to GG2 Prostate Cancer "Presentation" - Alastair Lamb
July 24, 2024
Details
Active Surveillance in Prostate Cancer: Rethinking Gleason Grade Group 1 "Presentation" - Daniel Lin
July 24, 2024
Details
Active Surveillance Challenges in Prostate Cancer Management "Presentation" - Laurence Klotz
July 24, 2024
Details
MRI Impact on Grade Group 1 Prostate Cancer Detection in Australia "Presentation" - Declan Murphy
July 24, 2024
Details
Active Surveillance vs. Watchful Waiting in Prostate Cancer Management "Presentation" - Caroline Moore
July 24, 2024
Details
Prostate Cancer Risk Assessment: Beyond Gleason Pattern Ratios "Presentation" - Andrew Vickers
July 24, 2024
Details
Modeling Prostate Cancer: Rethinking Grade Group 1 Classification "Presentation" - Ruth Etzioni
July 24, 2024
Details
The Debate on Prostate Cancer Grading: Addressing Underdiagnosis and Overdiagnosis Concerns "Presentation" - Andrew Vickers
July 24, 2024
Details
Rethinking Prostate Cancer Classification: The Cribriform Pattern Debate "Discussion"
July 24, 2024
Details
Alternative Payment Models in Prostate Cancer: Nomenclature Impact "Presentation" - CJ Stimpson
July 24, 2024
Details
Active Surveillance in Europe: Challenges and Heterogeneity "Presentation" - Derya Tilki
July 24, 2024
Details
Prostate Cancer in Africa: Pathology Outcomes and Risk Profiles "Presentation" - Mohamed Jalloh
July 24, 2024
Details
Prostate Cancer Diagnosis: MRI vs. Systematic Biopsy "Discussion"
July 24, 2024
Details
Racial Disparities in Prostate Cancer Active Surveillance Outcomes "Presentation" - Quoc-Dien Trinh
July 24, 2024
Details
Prostate Cancer Risk Assessment: Addressing Racial Equity Concerns "Discussion"
July 24, 2024
Details
Renaming Gleason 6 Prostate Cancer: Patient Perspectives and Impacts "Presentation" - Howard Wolinsky
July 24, 2024
Details
Patient Perspectives on Prostate Cancer: Quality of Life and Treatment Decisions "Presentation" - Leszek Izdebski
July 24, 2024
Details
CDC's Role in Advancing Prostate Cancer Active Surveillance Research "Presentation" - Ingrid Hall
July 24, 2024
Details
Prostate Cancer Nomenclature: Impact on Screening Guidelines "Presentation" - Timothy Wilt
July 24, 2024
Details
Rethinking Grade Group 1 Prostate Cancer: UK's Paradigm Shift "Presentation" - Hashim Ahmed
July 24, 2024
Details
Rethinking Prostate Cancer Diagnosis: UK vs US Approaches "Discussion"
July 24, 2024
Details
Prostate Cancer Markers: Challenges in Differentiating Low-Risk Cases "Discussion"
July 24, 2024
Details
Genomics in Prostate Cancer: Limitations in Active Surveillance "Presentation" - Felix Feng
July 24, 2024
Details
Redefining Prostate Cancer: The Debate on Grade Group 1 Classification "Discussion"
July 24, 2024
Details
Reclassifying Prostate Cancer: Clinical Implications of Grade Group 1 Nomenclature Change "Discussion"
July 24, 2024
Details
Prostate Cancer Nomenclature Change: Impact on Advocacy and Patient Care "Discussion"
July 24, 2024
Details
Prostate Cancer Nomenclature Change: Societal and Clinical Implications "Discussion"
July 24, 2024
Details
Prostate Cancer Management: Rethinking Active Surveillance and Nomenclature "Discussion"
July 24, 2024
Details
AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes - Cornelia Ding
July 22, 2024
Details
Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion"
July 22, 2024
Details
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
June 25, 2024
Details
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
June 20, 2024
Details
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
June 19, 2024
Details
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua
June 13, 2024
Details
Prostate Cancer Knowledge and Screening Barriers in Northern Tanzania: A Community-Based Study - Blandina Mmbaga & Nicholas Ngowi
June 5, 2024
Details
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
May 29, 2024
Details
Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence - Abhinav Khanna
May 29, 2024
Details
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
May 28, 2024
Details
Moonshot Initiative Funds Study on PSA-Based Risk-Stratified Prostate Cancer Screening - Siobhan Sutcliffe
May 20, 2024
Details
Staging High-Risk Prostate Cancer with PSMA PET: Strengths and Pitfalls - Irene Burger
April 24, 2024
Details
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
April 18, 2024
Details
Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian
April 18, 2024
Details
CEASAR Study Reveals Long-Term Quality of Life Outcomes for Localized Prostate Cancer Treatments - Daniel Barocas & Bashir Al Hussein Al Awamlh
March 15, 2024
Details
PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett
February 6, 2024
Details
ProtecT Trial 15-Year Data Shows Low Prostate Cancer Mortality Across Therapies for Localized Disease, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
January 18, 2024
Details
Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
January 18, 2024
Details
Radiation Outcomes Improve with Age in Localized Prostate Cancer - Mack Roach
January 11, 2024
Details
How Mental Health Disorders Impact Treatment Decisions in Localized Prostate Cancer - Yaw Nyame & Joshua Cabral
December 13, 2023
Details
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg
November 21, 2023
Details
PACE B Study Analysis: Acute and Late Toxicities in Prostate Cancer Radiotherapy - Ragu Ratnakumaran
October 10, 2023
Details
The Prognostic Value of PSA Levels Post-Radiation in Prostate Cancer - Praful Ravi
June 15, 2023
Details
Exploring Regional Variation in Genomic Testing and Imaging in Prostate Cancer - Michael S. Leapman
June 2, 2023
Details
Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm Phase 2 Trial - Eugene Shenderov
May 31, 2023
Details
Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis
May 23, 2023
Details
Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson
May 16, 2023
Details
Advancements in Prostate Cancer Screening: Inclusion of At-Risk Groups, Imaging & Biomarkers - An AUA Guidelines Update - Daniel Lin
May 11, 2023
Details
Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu
May 9, 2023
Details
15-Year Follow-Up of the ProtecT Trial: Discussing Results and Changes in Prostate Cancer Management, The ProtecT Trial - Oliver Sartor
May 9, 2023
Details
ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson
May 9, 2023
Details
Advancing Rectal Spacing in Prostate Cancer Radiation Therapy: The Benefits of Barrigel® - Neil Mariados
May 5, 2023
Details
Improving MRI for Localized Prostate Cancer Diagnosis: The Need for a Standardized and Quantitative MRI Approach - Tyler Seibert
May 3, 2023
Details
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases - Beyond the Abstract
March 22, 2023
Details
Treatment-Specific Out-of-Pocket Costs for Patients Undergoing Localized Prostate Cancer Journal Club - Zachary Klaassen
January 5, 2023
Details
Differences in Mental Health Outcomes According to the Treatment Received for Men Being Treated with Localized Prostate Cancer Journal Club - Zachary Klaassen
January 5, 2023
Details
Using MRI to Safely Prevent Unnecessary Protocol-Advised Repeat Biopsy During Active Surveillance Journal Club - Zachary Klaassen
January 5, 2023
Details
Comparing the Relative Benefits of Radiotherapy Dose Escalation ± Short-Term or Long-Term ADT as Treatment Intensification for Localized Prostate Cancer Journal Club - Zachary Klaassen
January 5, 2023
Details
10-year Results DART 01-05, High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localized Prostate Cancer Journal Club - Zachary Klaassen
December 15, 2022
Details
The Molecular Biology of Prostate Cancer - Christopher Barbieri
October 28, 2022
Details
DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
September 29, 2022
Details
The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider
September 15, 2022
Details
A Probing Conversation on Prostate Cancer Diagnosis and the Potential of Liquid Biopsies and Polygenic Risk Scores - Sanoj Punnen
August 24, 2022
Details
Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy
August 3, 2022
Details
How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer
August 2, 2022
Details
The ENACT Trial: Ezalutamide Monotherapy plus Active Surveillance vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Prostate Cancer - Neal Shore
July 27, 2022
Details
LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen
July 5, 2022
Details
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
June 24, 2022
Details
Genomic Risk Classification in Localized Prostate Cancer - Matthew Cooperberg
June 20, 2022
Details
Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas
June 2, 2022
Details
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
May 23, 2022
Details
Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb
May 15, 2022
Details
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
May 11, 2022
Details
The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
May 10, 2022
Details
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee
April 24, 2022
Details
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
March 29, 2022
Details
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
March 16, 2022
Details
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
March 10, 2022
Details
AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt
March 4, 2022
Details
AI-derived Digital Pathology-Based Biomarkers in Localized Prostate Cancer - Felix Feng
March 1, 2022
Details
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
February 4, 2022
Details
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
January 17, 2022
Details
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
December 16, 2021
Details
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
November 18, 2021
Details
NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen
November 10, 2021
Details
Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials – Todd Morgan
August 30, 2021
Details
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
August 18, 2021
Details
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
August 18, 2021
Details
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
August 18, 2021
Details
Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb
August 11, 2021
Details
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
July 18, 2021
Details
Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni
May 9, 2021
Details
Relugolix vs. Traditional ADT: A Comparative Analysis in the Setting of Definitive Therapy for Localized Disease - Ashley Ross
May 7, 2021
Details
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
February 16, 2021
Details
Prostate Active Surveillance Study (PASS) - Daniel Lin
November 2, 2020
Details
How Can We Accelerate Clinical Trial Accrual in Localized Prostate Cancer? - Brian F. Chapin
November 13, 2020
Details
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
October 4, 2020
Details
DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney
July 28, 2020
Details
The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. McKay
June 8, 2020
Details
Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll
March 13, 2020
Details
Study of Baseline PSA Screening of Men (45 years old) - Peter Albers
December 30, 2019
Details
Radiation Therapy Advances and Technology Overview - Daniel Spratt
December 16, 2019
Details
Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson
November 11, 2019
Details
Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer - June Chan
January 15, 2020
Details
Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg
November 6, 2019
Details
ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt
February 7, 2019
Details
Engagement in Long-Term Physical Activity and Lowering the Risk of Advanced Prostate Cancer - Lorelei Mucci
January 29, 2019
Details
Focal Therapy: Ready or Not - Herbert Lepor
December 1, 2018
Details
EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison
October 29, 2018
Details
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson
June 12, 2018
Details
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
May 21, 2018
Details
Active Surveillance: Who is the Right Patient? - Matt Cooperberg
April 17, 2018
Details